Clinical trial
Sep 2026
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
BACKGROUND RAS mutations, as a group, are the most common oncogenic drivers of non-small-cell lung cancer (NSCLC), and they occur in approximately 30% of patients. Whether daraxonrasib (RMC-6236) - an oral RAS(ON) multiselective, tri-complex inhibitor of guanosine triphosphate-bound mutant and wild-type RAS protein iso...
K. Arbour, Salman R. Punekar, Jia Luo et al.
· New England Journal of Medic... · 1 citation